CLINSTIUDYC ARESLULT S
A Study about Ravulizumab and Eculizumab in
Complement Inhibitor-naive Patients
with Paroxysmal Nocturnal Hemoglobinuria (PNH)
THANK YOU!
Alexion would like to thank
all of the patients, their families, and
caregivers who took part in this
clinical study. Taking part in studies
like this one contributes directly to
the discovery of new medicines for
people with PNH.
STUDY IDENTIFICATION INFORMATION
TREATMENTS STUDIED: 1) ravulizumab, also known as ALXN1210 (trade name: Ultomiris®)
2) eculizumab (trade name: Soliris®)
STUDY TITLE: A Phase 3, Randomized, Open-label, Active-controlled Study of ALXN1210 Versus Eculizumab
in Complement Inhibitor-naive Adult Patients with Paroxysmal Nocturnal Hemoglobinuria
STUDY NUMBERS: Europe, 2016-002025-11 | United States, NCT02946463 | Protocol, ALXN1210-PNH-301
L4 M
ATEXxION
ertara USA, Inc. 2020. Allrights r.